Skip to main content
Erschienen in: Journal of Endocrinological Investigation 6/2019

01.06.2019 | Original Article

Association of benign thyroid diseases with thyroid cancer risk: a meta-analysis of prospective observational studies

verfasst von: L. Liang, X.-C. Zheng, M.-J. Hu, Q. Zhang, S.-Y. Wang, F. Huang

Erschienen in: Journal of Endocrinological Investigation | Ausgabe 6/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Evidence showed that benign thyroid disease was one of the risk factors for thyroid cancer. However, the results of some studies were inconsistent and were previously meta-analyses of case–control studies. Therefore, we performed a meta-analysis of prospective studies to investigate the relationship between benign thyroid diseases and thyroid cancer risk.

Methods

All eligible studies were identified via systematic searches of multiple literature databases. The combined RR (relative risk)/HR (hazard ratio) or SIR (standardized incidence ratio) with 95% confidence interval was calculated. Heterogeneity was assessed with the I2 test. Publication bias and subgroup analyses were also performed.

Results

Twelve studies were eligible for inclusion in the meta-analysis. The pooled RR/HR of thyroid carcinoma in benign thyroid diseases was 4.39 (95% CI 3.22–5.55). The pooled SIR of thyroid carcinoma in benign thyroid diseases was 5.98 (95% CI 4.09–7.86). Subgroup analysis was performed using the type of benign thyroid diseases. Effect value was RR/HR: hyperthyroidism (RR/HR = 3.89, 95% CI = 1.69–6.08), hypothyroidism (RR/HR = 2.72, 95% CI = 1.04–4.41), and goiter (RR/HR = 22.18, 95% CI = 12.09–32.28). Effect value was SIR: hyperthyroidism (RR/HR = 5.96, 95% CI = 1.88–10.03), goiter (RR/HR = 7.65, 95% CI = 6.94–8.37), and thyroiditis (RR/HR = 3.25, 95% CI = 1.62–4.89).

Conclusions

Our study has shown that benign thyroid diseases might be associated with increased risk of thyroid cancer, especially in hyperthyroidism, hypothyroidism, and goiter. However, further investigation is needed to better understand the underlying biological mechanisms.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
4.
Zurück zum Zitat Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr (1987) A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79(1):1–12PubMed Ron E, Kleinerman RA, Boice JD Jr, LiVolsi VA, Flannery JT, Fraumeni JF Jr (1987) A population-based case-control study of thyroid cancer. J Natl Cancer Inst 79(1):1–12PubMed
5.
Zurück zum Zitat Franceschi S, Fassina A, Talamini R, Mazzolini A, Vianello S, Bidoli E, Serraino D, La Vecchia C (1989) Risk factors for thyroid cancer in northern Italy. Int J Epidemiol 18(3):578–584CrossRefPubMed Franceschi S, Fassina A, Talamini R, Mazzolini A, Vianello S, Bidoli E, Serraino D, La Vecchia C (1989) Risk factors for thyroid cancer in northern Italy. Int J Epidemiol 18(3):578–584CrossRefPubMed
11.
Zurück zum Zitat Gabalec F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, Ryska A, Cap J (2016) Impact of Hashimoto’s thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence. Endokrynol Polska 67(1):48–53. https://doi.org/10.5603/EP.a2016.0022 CrossRef Gabalec F, Srbova L, Nova M, Hovorkova E, Hornychova H, Jakubikova I, Ryska A, Cap J (2016) Impact of Hashimoto’s thyroiditis, TSH levels, and anti-thyroid antibody positivity on differentiated thyroid carcinoma incidence. Endokrynol Polska 67(1):48–53. https://​doi.​org/​10.​5603/​EP.​a2016.​0022 CrossRef
13.
Zurück zum Zitat Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E (1999) A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10(6):583–595CrossRefPubMed Franceschi S, Preston-Martin S, Dal Maso L, Negri E, La Vecchia C, Mack WJ, McTiernan A, Kolonel L, Mark SD, Mabuchi K, Jin F, Wingren G, Galanti R, Hallquist A, Glattre E, Lund E, Levi F, Linos D, Ron E (1999) A pooled analysis of case-control studies of thyroid cancer. IV. Benign thyroid diseases. Cancer Causes Control 10(6):583–595CrossRefPubMed
17.
Zurück zum Zitat Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, Moher D, Becker BJ, Sipe TA, Thacker SB (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283(15):2008–2012CrossRefPubMed
18.
Zurück zum Zitat Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed Higgins JP, Thompson SG (2002) Quantifying heterogeneity in a meta-analysis. Stat Med 21(11):1539–1558CrossRefPubMed
19.
21.
Zurück zum Zitat Iribarren C, Haselkorn T, Tekawa IS, Friedman GD (2001) Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93(5):745–750CrossRefPubMed Iribarren C, Haselkorn T, Tekawa IS, Friedman GD (2001) Cohort study of thyroid cancer in a San Francisco Bay area population. Int J Cancer 93(5):745–750CrossRefPubMed
23.
Zurück zum Zitat Adams MJ, Shore RE, Dozier A, Lipshultz SE, Schwartz RG, Constine LS, Pearson TA, Stovall M, Thevenet-Morrison K, Fisher SG (2010) Thyroid cancer risk 40+ years after irradiation for an enlarged thymus: an update of the Hempelmann cohort. Radiat Res 174(6):753–762. https://doi.org/10.1667/RR2181.1 CrossRefPubMed Adams MJ, Shore RE, Dozier A, Lipshultz SE, Schwartz RG, Constine LS, Pearson TA, Stovall M, Thevenet-Morrison K, Fisher SG (2010) Thyroid cancer risk 40+ years after irradiation for an enlarged thymus: an update of the Hempelmann cohort. Radiat Res 174(6):753–762. https://​doi.​org/​10.​1667/​RR2181.​1 CrossRefPubMed
27.
Zurück zum Zitat Holm LE, Blomgren H, Löwhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312(10):601–604CrossRefPubMed Holm LE, Blomgren H, Löwhagen T (1985) Cancer risks in patients with chronic lymphocytic thyroiditis. N Engl J Med 312(10):601–604CrossRefPubMed
28.
Zurück zum Zitat Mellemgaard A, From G, Jørgensen T, Johansen C, Olsen JH, Perrild H (1998) Cancer risk in individuals with benign thyroid disorders. Thyroid 8(9):751–754CrossRefPubMed Mellemgaard A, From G, Jørgensen T, Johansen C, Olsen JH, Perrild H (1998) Cancer risk in individuals with benign thyroid disorders. Thyroid 8(9):751–754CrossRefPubMed
32.
Zurück zum Zitat Moazezi Z, Mahmoudi M, Yahyahpour Y, Alaleh A (2011) Risk factors of thyroid cancer in Babol, Northern Iran. Casp J Intern Med 2(1):171–177 Moazezi Z, Mahmoudi M, Yahyahpour Y, Alaleh A (2011) Risk factors of thyroid cancer in Babol, Northern Iran. Casp J Intern Med 2(1):171–177
34.
Zurück zum Zitat Rees Smith B, McLachlan SM, Furmaniak J (1988) Autoantibodies to the thyrotropin receptor. Endocr Rev 9(1):106–121CrossRefPubMed Rees Smith B, McLachlan SM, Furmaniak J (1988) Autoantibodies to the thyrotropin receptor. Endocr Rev 9(1):106–121CrossRefPubMed
35.
Zurück zum Zitat Valenti TM, Macchia E, Pisa R, Bucalo ML, Russo V, Colletti I, Compagno V, Abbadi V, Donatelli M (1999) Toxic adenoma and papillary thyroid carcinoma in a patient with Graves’ disease. J Endocrinol Investig 22(9):701–704CrossRef Valenti TM, Macchia E, Pisa R, Bucalo ML, Russo V, Colletti I, Compagno V, Abbadi V, Donatelli M (1999) Toxic adenoma and papillary thyroid carcinoma in a patient with Graves’ disease. J Endocrinol Investig 22(9):701–704CrossRef
36.
Zurück zum Zitat Belfiore A, Garofalo MR, Guiffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R (1990) Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 70(4):830–835CrossRefPubMed Belfiore A, Garofalo MR, Guiffrida D, Runello F, Filetti S, Fiumara A, Ippolito O, Vigneri R (1990) Increased aggressiveness of thyroid cancer in patients with Graves’ disease. J Clin Endocrinol Metab 70(4):830–835CrossRefPubMed
38.
Zurück zum Zitat Kumar A, Klinge CM, Goldstein RE (2010) Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors α and β. Int J Oncol 36(5):1067–1080PubMed Kumar A, Klinge CM, Goldstein RE (2010) Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors α and β. Int J Oncol 36(5):1067–1080PubMed
39.
Zurück zum Zitat Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warschauer ME, Wong FL, Boice JD Jr (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280(4):347–355CrossRefPubMed Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, Harris BS 3rd, Hoffman DA, McConahey WM, Maxon HR, Preston-Martin S, Warschauer ME, Wong FL, Boice JD Jr (1998) Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study Group. JAMA 280(4):347–355CrossRefPubMed
40.
Zurück zum Zitat Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353(9170):2111–2115CrossRefPubMed Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P (1999) Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 353(9170):2111–2115CrossRefPubMed
42.
Zurück zum Zitat Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93(3):809–814CrossRefPubMed Haymart MR, Repplinger DJ, Leverson GE, Elson DF, Sippel RS, Jaume JC, Chen H (2008) Higher serum thyroid stimulating hormone level in thyroid nodule patients is associated with greater risks of differentiated thyroid cancer and advanced tumor stage. J Clin Endocrinol Metab 93(3):809–814CrossRefPubMed
43.
Zurück zum Zitat Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L, Kaaks R, Lukanova A, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Lund E, Quirós JR, Agudo A, Molina E, Larrañaga N, Navarro C, Ardanaz E, Manjer J, Almquist M, Sandström M, Hennings J, Khaw KT, Schmidt J, Travis RC, Byrnes G, Scalbert A, Romieu I, Gunter M, Riboli E, Franceschi S (2014) Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 106(6):dju097CrossRefPubMed Rinaldi S, Plummer M, Biessy C, Tsilidis KK, Østergaard JN, Overvad K, Tjønneland A, Halkjaer J, Boutron-Ruault MC, Clavel-Chapelon F, Dossus L, Kaaks R, Lukanova A, Boeing H, Trichopoulou A, Lagiou P, Trichopoulos D, Palli D, Agnoli C, Tumino R, Vineis P, Panico S, Bueno-de-Mesquita HB, Peeters PH, Weiderpass E, Lund E, Quirós JR, Agudo A, Molina E, Larrañaga N, Navarro C, Ardanaz E, Manjer J, Almquist M, Sandström M, Hennings J, Khaw KT, Schmidt J, Travis RC, Byrnes G, Scalbert A, Romieu I, Gunter M, Riboli E, Franceschi S (2014) Thyroid-stimulating hormone, thyroglobulin, and thyroid hormones and risk of differentiated thyroid carcinoma: the EPIC study. J Natl Cancer Inst 106(6):dju097CrossRefPubMed
44.
Zurück zum Zitat Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P (2010) The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 17(30):3449–3461CrossRefPubMed Bozec A, Lassalle S, Hofman V, Ilie M, Santini J, Hofman P (2010) The thyroid gland: a crossroad in inflammation-induced carcinoma? An ongoing debate with new therapeutic potential. Curr Med Chem 17(30):3449–3461CrossRefPubMed
Metadaten
Titel
Association of benign thyroid diseases with thyroid cancer risk: a meta-analysis of prospective observational studies
verfasst von
L. Liang
X.-C. Zheng
M.-J. Hu
Q. Zhang
S.-Y. Wang
F. Huang
Publikationsdatum
01.06.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Endocrinological Investigation / Ausgabe 6/2019
Elektronische ISSN: 1720-8386
DOI
https://doi.org/10.1007/s40618-018-0968-z

Weitere Artikel der Ausgabe 6/2019

Journal of Endocrinological Investigation 6/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.